Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Olaratumab

EU orphan designation number: EU/3/15/1447   
Active ingredient: Olaratumab
Indication: Treatment of soft tissue sarcoma
Sponsor: Eli Lilly Nederland B.V.
Papendorpseweg 83, 3528 BJ Utrecht, Nederland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Lartruvo on 09/11/2016 with the number EU/1/16/1143

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
16/02/2015 Orphan designation EMA/OD/266/14 (2015)952 of 12/02/2015
19/02/2016 Change of name and/or address of sponsor